Amgen shelves Irish manufacturing facility plans

Much to Ireland's disappointment, Amgen said it would "postpone indefinitely" a planned €800 million manufacturing facility in County Cork. The biotech giant said that a review of its business plan and the evolving business environment led to the decision. All 75 jobs in Ireland will be eliminated. The facility was to bring 1,100 jobs to the country. Irish officials were quick to point out that Amgen's decision was related to the company's business goals and not to the economic environment in Ireland.

"We understand that this is a very disappointing development for our employees, the government, the neighbors around our site and the broader Cork community," said Mark Sawyer, general manager and vice president of Operations, Amgen Technology Ireland. Amgen said that it expects to maintain ownership of the site, though other sources say the biotech is likely to sell. Amgen is in the midst of a company-wide restructuring designed to cut about 14 percent of its workforce and cut a billion dollars in expenses.

- see the release on the decision
- read the report from the Irish Independent

Related Articles:
Amgen selects manufacturing site. Report
Rhode Island feeling effects of Amgen cuts. Report
At corporate HQ, Amgen drops the axe. Report
Amgen makes big workforce, budget cuts. Report
Ireland trumpets Pfizer biotech facility. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.